The World Health Assembly’s historic resolution on steatotic liver disease introduces three critical shifts in global health strategy that healthcare providers and policymakers must understand. First, this is the first WHO resolution specifically addressing SLD and its integration into noncommunicable disease frameworks, elevating fatty liver disease from a neglected condition to a priority health concern affecting 1.5 billion people worldwide.
Second, the resolution acknowledges that SLD is among the most common liver conditions globally, yet has been systematically overlooked. This recognition opens pathways for funding, research, and clinical attention previously unavailable.
Third, the resolution’s practical implications demand action: member states must enhance surveillance systems to identify SLD cases, implement prevention strategies addressing underlying metabolic risk factors, and strengthen healthcare infrastructure for diagnosis and management. These provisions directly impact how healthcare systems allocate resources and train clinicians to address this pandemic.
For practitioners, administrators, and public health officials, this resolution represents a mandate to integrate SLD into existing noncommunicable disease programs and to prioritize patient screening and intervention strategies.
Read the full article on GMJ Newsroom.
Was this article helpful?
